In Reply We read with great interest the letter by Gao et al in which several issues are raised regarding our randomized clinical trial (RCT),1 particularly considering the negative results of a double-blind RCT, the Combined Gefitinib and Metformin Therapy study.2 Importantly, all patients were randomized as per protocol. Nonetheless, at the time of the submission deadline for abstracts for the 2018 American Society of Clinical Oncology annual meeting, the data capture in the database was incomplete, and the analysis was performed with the information captured to that date, though all patients had been recruited at this point. In the following weeks, all data were captured in time to be analyzed and presented in a publicly available poster during the meeting. The information regarding allocation presented in the poster and the published article is exactly the same.
Identify all potential conflicts of interest that might be relevant to your comment.
Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.
Err on the side of full disclosure.
If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.
Not all submitted comments are published. Please see our commenting policy for details.
Arrieta O, Ramirez-Tirado LA, Zatarain-Barrón ZL. Metformin Plus Tyrosine Kinase Inhibitors in Epidermal Growth Factor Receptor–Mutated Non–Small Cell Lung Cancer—Reply. JAMA Oncol. Published online March 12, 2020. doi:10.1001/jamaoncol.2020.0062
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: